利图西马布用于移植后淋巴增殖障碍 - 治疗,预防或预防?
Jan Storek1, Julian Lindsay2,3
1University of Calgary, Calgary, AB, Canada. jstorek@ucalgary.ca.
Bone marrow transplantation
|November 24, 2023
概括
降低移植后淋巴增殖性疾病 (PTLD) 死亡率的策略包括没有爱斯坦-巴尔病毒 (EBV) 监测的治疗,及时治疗,预防性治疗和预防. 预防性治疗或预防目前是高风险患者的首选.
科学领域:
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
- 在瘤学瘤学.
背景情况:
- 移植后淋巴增殖障碍 (PTLD) 在移植受体中构成显著的死亡风险.
- 有效的策略对于管理PTLD和改善患者结果至关重要.
- 爱斯坦-巴尔病毒 (EBV) 在PTLD的发病过程中起着核心作用.
研究的目的:
- 审查和比较PTLD的不同管理策略.
- 分析每个PTLD治疗方法的优缺点.
- 根据患者的风险,提供关于最佳PTLD管理的见解.
主要方法:
- 审查关于PTLD管理策略的现有文献.
- 四种不同的方法的比较:没有EBV监测的治疗,即时治疗,预防性治疗和预防.
- 评估EBVDNAemia监测和rituximab管理的作用.
主要成果:
- 没有一个单一的PTLD管理策略被确定为优越的.
- 预防性治疗和预防目前是高风险PTLD患者的首选.
- 没有EBV的治疗 监测可能成为新型治疗耐火性PTLD的可行性.
结论:
- 选择PTLD管理策略应根据患者的风险因素进行个性化.
- 需要进行进一步的研究,以确定PTLD预防和治疗的最佳方法.
- 在PTLD疗法的进步可以扩大不同的管理策略的适用性.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143